Top Healthcare Stocks by UQS Score

1153 stocks scored · Last updated July 9, 2026

Healthcare is one of the few sectors where demand is structurally guaranteed — aging populations, chronic disease prevalence, and innovation-driven treatment cycles create persistent tailwinds regardless of economic conditions. But the sector spans an enormous range: from cash-burning biotech startups hoping for FDA approval to diversified pharma giants with decades of patent-protected revenue. The UQS model cuts through this noise by scoring actual financial performance and balance sheet health, not pipeline potential. Companies ranked highest here have already demonstrated they can turn scientific innovation into profitable, sustainable businesses.

Healthcare Sector Characteristics

Healthcare encompasses pharmaceuticals, biotechnology, medical devices, managed care, hospital systems, and life science tools. What makes the sector unique for scoring is its bimodal distribution: large pharma companies tend to have exceptional quality scores (high margins from patented drugs) but modest growth scores (patent cliffs create revenue headwinds), while smaller biotech companies show the inverse pattern. Medical device companies often hit a sweet spot — consistent revenue growth with defensible market positions and recurring consumable revenue. The UQS model captures these dynamics by scoring each metric independently, so a pharma company isn't penalized for slow growth if it excels everywhere else.

Scoring note: Healthcare uses consumer-sector thresholds (25% ROIC, 30% operating margin) because pharmaceutical margins vary widely depending on patent cliffs and R&D spending cycles. Biotech companies with negative earnings can still score well on growth and moat if they have strong pipelines and low debt.

Healthcare Sector Score Overview

71

Avg UQS Score

84

Avg Quality

44

Avg Moat

74

Avg Growth

87

Avg Risk

74

Avg Valuation

Top Healthcare Stocks: Who Leads and Why

#1DOCSDoximity, Inc.77

Doximity, Inc. leads healthcare with a 77 UQS score, driven by a 90 quality rating that reflects superior margins and capital returns. Its moat score of 58 confirms deep competitive advantages in its therapeutic areas.

#2CPRXCatalyst Pharmaceuticals, Inc.77

Catalyst Pharmaceuticals, Inc. scores 77 overall, balancing strong profitability (quality: 90) with a robust balance sheet (risk: 100). A well-diversified revenue base supports scoring consistency.

#3INCYIncyte Corporation76

At 76, Incyte Corporation earns the third spot with notable strength in valuation (85) — suggesting the market may be underpricing its fundamentals relative to the quality of the business.

#4HRMYHarmony Biosciences Holdings, Inc.76

Harmony Biosciences Holdings, Inc. scores 76 with balanced pillar scores, indicating a well-rounded healthcare business with no major scoring weaknesses.

#5RMDResMed Inc.73

ResMed Inc. scores 73 with balanced pillar scores, indicating a well-rounded healthcare business with no major scoring weaknesses.

Full Healthcare Ranking: Top 25 Stocks

#	Stock	UQS	Q	M	G	R	V
1	DOCSDoximity, Inc.	77	90	58	71	100	72
2	CPRXCatalyst Pharmaceuticals, Inc.	77	90	42	81	100	83
3	INCYIncyte Corporation	76	91	44	74	100	85
4	HRMYHarmony Biosciences Holdings, Inc.	76	78	43	79	98	99
5	RMDResMed Inc.	73	90	52	62	100	66
6	AUPHAurinia Pharmaceuticals Inc.	73	93	41	71	91	76
7	ADMAADMA Biologics, Inc.	72	94	46	70	87	70
8	ARGXargenx SE	72	69	55	100	100	37
9	VEEVVeeva Systems Inc.	71	71	52	82	100	59
10	GLPG.ASLakefront Biotherapeutics	71	65	50	61	100	99
11	RIGLRigel Pharmaceuticals, Inc.	70	100	35	66	88	97
12	NUTXNutex Health, Inc.	70	93	32	69	76	100
13	CRMDCorMedix Inc.	70	97	46	53	99	64
14	VRTXVertex Pharmaceuticals Incorporated	70	83	55	63	100	49
15	NAGENiagen Bioscience Inc	69	61	35	91	100	82
16	LLYEli Lilly and Company	69	86	58	100	53	36
17	UTHRUnited Therapeutics Corporation	69	83	53	48	100	70
18	ANIPANI Pharmaceuticals, Inc.	69	62	32	100	74	95
19	DXCMDexCom, Inc.	69	84	50	76	79	55
20	CELG-RIBristol-Myers Squibb Company Ce	69	92	48	72	28	100
21	EXELExelixis, Inc.	68	97	41	54	82	71
22	NBIXNeurocrine Biosciences, Inc.	68	81	38	90	73	62
23	VXRTVaxart, Inc.	67	87	19	63	88	98
24	ALNYAlnylam Pharmaceuticals, Inc.	67	71	53	100	72	35
25	CGENCompugen Ltd.	67	83	25	63	82	98

Filter all 1153+ healthcare stocks in the full directory

Browse All Stocks

Frequently Asked Questions About Healthcare Stocks

How does UQS handle biotech companies with no revenue?

Pre-revenue biotech companies typically score low overall because most UQS metrics require financial data (revenue, margins, earnings). Their quality score will be near zero, and growth metrics that depend on trailing revenue won't have data. However, if a biotech has low debt and strong cash reserves, it can score reasonably on risk. The moat score, being AI-driven, can also recognize strong IP portfolios and regulatory moats even for pre-revenue companies.

Why do healthcare stocks often score high on quality?

Pharmaceutical companies with patent-protected drugs enjoy some of the highest margins in the market — gross margins of 70-80% are common. Patents create temporary monopolies that allow premium pricing, and the regulatory approval process creates enormous barriers to entry. These structural advantages directly translate into high ROIC, wide operating margins, and strong free cash flow generation — exactly what the quality pillar measures.

What impact do patent cliffs have on UQS scores?

Patent expiration directly affects growth scores as revenue from blockbuster drugs declines. Quality scores may also dip as margins compress from generic competition. However, well-managed pharma companies with diversified pipelines often maintain their overall UQS scores by replacing expiring revenue with new drug launches. The three-year revenue CAGR in the growth pillar helps distinguish between transient patent cliff effects and structural decline.